Mechanism of Action
Trehalose acts on cellular renewal through a pathway distinct from most known inducers. Where fasting or caloric restriction trigger cellular recycling by signaling an energy deficit, trehalose takes a different route. It interacts with glucose transporters on the cell surface, altering internal signals related to sugar availability.
This interaction triggers a cascade of cellular responses. The cell activates its internal recycling systems, the autophagosomes (specialized vesicles that encapsulate and degrade damaged components). The result is more efficient clearance of aggregated proteins, failing organelles and accumulated metabolic debris.
Trehalose also possesses a chemical chaperone property. In solution, it stabilizes protein conformation by reinforcing the network of water molecules surrounding them. This dual action (recycling support and direct stabilization) makes it a relevant molecule for maintaining protein homeostasis with age.
Key Benefits
- Moderate
A sugar that is gentler on blood sugar: its glycemic index is estimated at 38, well below glucose or sucrose. Multiple human tolerance studies confirm this favorable metabolic profile.
- Moderate
Proteins that keep their shape under stress: trehalose's chemical chaperone role is among the best-characterized features of the molecule, documented across several thousand publications.
- Emerging
The cell's internal recycling, an active avenue: converging preclinical studies and Phase 2 clinical trials explore trehalose's potential to support it, through a pathway independent of caloric restriction.
- Emerging
An effect measured in the liver: preclinical data published in Science Signaling show that trehalose modulates glucose transport inside liver cells. This action contributes to lipid metabolism in the liver.
Dosage & Forms
Trehalose exists in a single supplemental form: the dihydrate. Unlike other bioactives where the galenic choice influences bioavailability, this molecule presents no competing variants.
Intestinal trehalase partially cleaves trehalose into two glucose molecules. The fraction that escapes this hydrolysis exerts the biological effects on cellular recycling. This fraction varies according to individual enzymatic activity.
Preclinical studies and ongoing clinical trials use oral doses ranging from 2 to 12 g per day. Protocols targeting protein renewal support typically use 5 to 10 g per day, in one to two doses. Intake with a meal does not significantly influence absorption.
In the Singular Formula
Inclusion rationale
Non-reducing disaccharide composed of two glucose molecules linked in alpha,alpha-1,1. Present in mushrooms, yeasts and certain organisms capable of surviving near-total dehydration: tardigrades and so-called 'resurrection plants.' It is precisely this molecular stabilization property under extreme conditions that distinguishes trehalose from other sugars. During dehydration, trehalose forms a vitreous matrix around proteins and lipid membranes, replacing water molecules in hydrogen bond interactions and preserving the native three-dimensional conformation of biomolecules. This unique capacity for biological vitrification is exploited in biotechnology to stabilize vaccines, enzymes and therapeutic proteins without a cold chain. In the context of longevity, trehalose is studied for its ability to promote cellular autophagy, the process by which the cell eliminates its damaged or dysfunctional components. This fundamental maintenance mechanism naturally declines with age, contributing to the accumulation of cellular debris and progressive tissue dysfunction.
Selected form
Trehalose dihydrate, a non-reducing disaccharide composed of two glucose molecules linked by an alpha-1,1 bond. Naturally found in mushrooms, yeast and certain extremophile organisms. Unlike sucrose, its symmetrical bond provides remarkable stability against heat and acidity. Trehalose protects protein and lipid structures during desiccation, a well-documented mechanism in cell biology. Its sweetening power is approximately 45% that of sucrose. Quality: non-GMO, no excipient.
Formula dosage
0 to 6 g.
Synergies in the formula
Safety & Precautions
Trehalose has a considerable history of use in human nutrition. Authorized as a Novel Food in the European Union, it is backed by comprehensive toxicological data. Human tolerance studies have not identified significant adverse effects at common dietary doses.
Some individuals exhibit reduced intestinal trehalase activity. In these individuals, high intake may cause transient digestive discomfort (bloating, gas) related to colonic fermentation of the unhydrolyzed fraction. This phenomenon is analogous to lactose intolerance and remains benign.
Trehalose is not recommended for individuals with known trehalose intolerance (trehalase deficiency). Diabetics or those following carbohydrate-controlled diets should account for its caloric value (4 kcal/g, like other carbohydrates). No significant drug interactions have been documented to date. During pregnancy, breastfeeding or in case of any particular health condition, prior medical advice is recommended.
Scientific Studies
| Authors | Year | Type | Journal | |
|---|---|---|---|---|
| Richards AB et al. | 2002 | Systematic Review | Food and Chemical Toxicology | View on PubMed |
Trehalose: a review of properties, history of use and human tolerance, and results of multiple safety studies Comprehensive review of trehalose properties, history of dietary use and human tolerance data, concluding with a favorable safety profile. | ||||
| Sarkar S et al. | 2007 | Preclinical Study | Journal of Biological Chemistry | View on PubMed |
Trehalose, a novel mTOR-independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein Foundational paper demonstrating that trehalose induces autophagy through an independent pathway and accelerates clearance of aggregated proteins in cellular models. | ||||
| Jain NK, Roy I | 2009 | Systematic Review | Protein Science | View on PubMed |
Effect of trehalose on protein structure Review of protein stabilization mechanisms by trehalose, including water molecule replacement and vitrification. | ||||
| DeBosch BJ et al. | 2016 | Preclinical Study | Science Signaling | View on PubMed |
Trehalose inhibits solute carrier 2A (SLC2A) proteins to induce autophagy and prevent hepatic steatosis Identification of trehalose mechanism of action via glucose transporters, with effects on hepatic autophagy and steatosis in preclinical models. | ||||
| Hosseinpour-Moghaddam K et al. | 2018 | Systematic Review | Journal of Cellular Physiology | View on PubMed |
Autophagy induction by trehalose: Molecular mechanisms and therapeutic impacts Review of molecular mechanisms by which trehalose induces autophagy and its potential across various research contexts. | ||||